Preview

User

Not a user? Register with this site Forgot your password?

Current Pediatrics

Advanced search

EFFECTIVENESS OF INFLIXIMAB IN PATIENTS WITH JUVENILE ANKYLOSING SPONDYLARTHRITIS

Abstract

The objective of open-labeled study was estimation of effectiveness and safety of infliximab — monoclonal antibodies to tumor necrosis factor (TNF) - in treatment of 48 patients with juvenile ankylosing spondylarthritis. Duration of observation was 6 weeks — 1,5 years. Anticytokine treatment was administrated on the ground of therapy with immunosuppressive agents in 96% of patients. Infliximab was administrated in median dose 7,4 ± 3,7 mg/kg of body weight by standard scheme (0–2–6 — week and further every 8 weeks) intravenously. Results of a trial showed that infliximab has evident anti-inflammatory effect. Treatment with infliximab provided development of remission of articular syndrome, decreasing and normalization of laboratory indices of activity of disease, the rate of disability, and increasing of quality of life in 84% of patients. Effect of this medication was registered after first infusion and continued during all period of follow up. Adverse effects included transfusion reactions: fever, head ache, nausea/vomiting in 10% of patients, allergic arthritis — in 2% of patients. Thus, treatment of infliximab is pathogenetically grounded, effective and safe in patients with juvenile ankylosing spondylarthritis.
Key words: children, juvenile ankylosing spondylarthritis, infliximab, treatment.
(Voprosy sovremennoi pediatrii — Current Pediatrics. 2009;8(2):20-26)

About the Authors

A.L. Kozlova
Scientific Center of Children's Health, Russian Academy of Medical Sciences, Moscow
Russian Federation


E.I. Alexeeva
Scientific Center of Children's Health, Russian Academy of Medical Sciences, Moscow
Russian Federation


S.I. Valieva
Scientific Center of Children's Health, Russian Academy of Medical Sciences, Moscow
Russian Federation


T.M. Bzarova
Scientific Center of Children's Health, Russian Academy of Medical Sciences, Moscow
Russian Federation


A.M. Chomakhidze
Scientific Center of Children's Health, Russian Academy of Medical Sciences, Moscow
Russian Federation


K.B. Isaeva
Scientific Center of Children's Health, Russian Academy of Medical Sciences, Moscow
Russian Federation


R.V. Denisova
Scientific Center of Children's Health, Russian Academy of Medical Sciences, Moscow
Russian Federation


E.Yu. Gudkova
Scientific Center of Children's Health, Russian Academy of Medical Sciences, Moscow
Russian Federation


A.O. Lisitsin
Scientific Center of Children's Health, Russian Academy of Medical Sciences, Moscow
Russian Federation


References

1. Бочкова А.Г. Анкилозирующий спондилит. М.: Институт ревматологии РАМН. 2005. С. 3–26.

2. Никишина И.П. Ювенильный анкилозирующий спондилоартрит. Практическое руководство по детским болезням. Под общей ред. В.Ф. Коколиной, А.Г. Румянцева. М.: Медпрактика. 2004. Том III. С. 620–649.

3. Кузьмина Н.Н. Ювенильный анкилозирующий спондилоартрит. Детская ревматология: Руководство для врачей. Под ред. А.А. Баранова, Л.К. Баженовой. М.: Медицина. 2002. С. 141–182.

4. Fearon U., Veale D.J. Pathogenesis of psoriatic arthritis. Clin. Exp.Dermatol. 2001; 26: 333–337.

5. Kalden J.R. Emerging role of anti–tumor necrosis factor therapy in rheumatic diseases. Arthritis Res. 2002; 4 (Suppl. 2): 534–540.

6. Mease P., Kivitz A.J., Burch F.X. et al. Etanercept treatment of psoriatic arthritis: sarety, efficacy, and effect on disease progression. Arthritis Rheum. 2004; 50: 2264–2272.

7. Beutler B.A. The role of tumor necrosis factor in health and disease. J. Rheumatol. 1999; 26 (Suppl. 57): 16–21.

8. Granfors K., Marker-Hermann E., De Kayser F. The cutting edge of spondiloarthropathy research in the millennium. Arthritis Rheum. 2002; 46 (3): 606–613.

9. Mease P., Antoni C.E. Psoriatic arthris treatment: biological response modifiers. Ann. Rheum. Dis. 2005; 64 (Suppl. 2): 78–82.

10. Бадокин В.C. Эффективность ингибиторов биологического ответа при псориатическом артрите. Врач. 2005; 5: 48–52.

11. Reed M.R., Taylor A.L. Tumor necrosis factor inhibitors in ankylosing spondylitis. Intern. Med. J. 2008; 38 (10): 781–789.

12. Haibel H., Song I.H., Rudwaleit M. et al. Multicenter open-label study with infliximab in active ankylosing spondylitis over 28 week in daily practice. Clin. Exp. Rheumatol. 2008; 26 (2): 247–252.

13. Braun J., Deodhar A., Dijkmans B., et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two year period. Arthritis Rheum. 2008; 59 (9): 1270–1278.

14. Griffoul I., Giraudeau B., Mulleman D. et al. Infliximab for treating axial spondylarthropathy in everyday practice. Joint Bone Spine. 2009; 76 (1): 39–43.

15. Румянцева О.А. Исследование эффективности, безопасности и переносимости инфликсимаба у больных анкилозирующим спондилитом (предварительные результаты). Научно-практическая ревматология. 2006; 4: 11–19.

16. Preur A.M., Dougados M., Listrat V., Amor B. Evaluation of four sets of criteria for spondyloarthropathy in children: a multicenter cross sectional European study. Arthritis Rhem. 1992; 35 (Suppl.): 190.

17. Ruperto N., Lovell D.J., Quartier P., et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double blind, placebo controlled withdrawal trial. Lancet. 2008; 372 (9636): 383–391.


Review

For citations:

Kozlova A., Alexeeva E., Valieva S., Bzarova T., Chomakhidze A., Isaeva K., Denisova R., Gudkova E., Lisitsin A. EFFECTIVENESS OF INFLIXIMAB IN PATIENTS WITH JUVENILE ANKYLOSING SPONDYLARTHRITIS. Current Pediatrics. 2009;8(2):20-26.

Views: 563


ISSN 1682-5527 (Print)
ISSN 1682-5535 (Online)

"Paediatrician" Publishers LLC
Unit 4/1, 54–4 Vavilova Street, 119296, Moscow, Russian Federation
Web-site: http://www.spr-journal.ru/
E-mail: vsp@spr-journal.ru
Tel.: +7 (499) 132-02-17
Мob.: +7 (916) 650-07-42

Яндекс.Метрика

Processing of personal data
supported by NEICON (Elpub lab)